Quantum Cyber N.V. income statement QUCY

It recorded a net loss of $11.0 million. Diluted earnings per share were -$0.62.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Research and development
5
0
Selling, general and administrative
5
2
Operating income
-10
-2
Interest expense
0
0
Other income (expense)
-0
-0
Pretax income
-10
-2
Net income
-11
-5
Basic EPS
-0.62
-0.43
Diluted EPS
-0.62
-0.43
Weighted average shares, basic
18
12
Weighted average shares, diluted
18
12
Other measures
Depreciation and amortization
-0
0
EBITDA
-10
-2
Interest coverage
-1,371.94x
-162.31x
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
QUCY (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Netherlands
Headquarters
Mainz
SEC filer status
, Emerging growth company
SEC CIK
1874252
Former names
MAINZ BIOMED N.V. (until Apr 15, 2026); Mainz Biomed B.V. (until Nov 12, 2021)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.